Role of SPARC in bone remodeling and cancer-related bone metastasis

Nilza Ribeiro1, Susana R Sousa, Rolf A Brekken

  • 1INEB-Instituto de Engenharia Biomédica, Universidade do Porto, Rua do Campo Alegre, 823, 4150-180, Porto, Portugal; Departamento de Engenharia Metalúrgica e de Materiais, Faculdade de Engenharia (FEUP), Universidade do Porto, Rua Roberto Frias, s/n, 4200-465, Porto, Portugal.

Insights

Secreted protein acidic rich in cysteine (SPARC) is a potential target for bone diseases like osteoporosis and cancer metastasis. Further research into SPARC

Area of Science:

  • Biochemistry
  • Oncology
  • Orthopedics

Background:

  • Bone diseases including infections, tumors, and osteoporosis are significant socioeconomic concerns.
  • Secreted protein acidic rich in cysteine (SPARC), a matricellular glycoprotein, is implicated in bone remodeling, mineralization, and tumor progression.
  • The precise role of SPARC in these processes remains poorly understood and debated.

Purpose of the Study:

  • To review current knowledge on SPARC's activity in bone remodeling, tumorigenesis, and bone metastasis.
  • To highlight SPARC's potential as a therapeutic target for bone-related conditions.

Main Methods:

  • Literature review of existing research on SPARC and bone biology.
  • Analysis of SPARC's involvement in tissue remodeling, cell turnover, and mineralization.
  • Examination of SPARC's role in primary bone tumors and cancer-related bone metastasis.

Main Results:

  • SPARC is associated with various aspects of bone biology, including development, repair, and mineralization.
  • SPARC's function in bone tumorigenesis and metastasis is complex and requires further elucidation.
  • Contradictory findings exist regarding SPARC's specific effects in different bone contexts.

Conclusions:

  • Understanding SPARC's multifaceted roles is crucial for developing effective therapeutic strategies.
  • SPARC presents a promising target for novel treatments aimed at bone regeneration and combating bone metastasis.
  • Future research should focus on clarifying SPARC's mechanisms to enable targeted anti-cancer and bone-healing therapies.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...